Xiao Wei

68 Ga-PSMA-11 PET as a gate-keeper for the treatment of metastatic prostate cancer with radium-223: proof of concept

M. Essler, S. Hauser, A. Yordanova, 2016 .

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride

R. Fimmers, M. Essler, S. Hauser, 2017, Oncotarget.

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Rolf Fimmers, Markus Essler, Anna Yordanova, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

R. Fimmers, M. Essler, S. Hauser, 2017, Oncotarget.

Radionuclide intake risks in the clinical administration of 223RaCl2

R. Bundschuh, M. Essler, H. Ahmadzadehfar, 2019, Journal of radiological protection : official journal of the Society for Radiological Protection.

68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept

M. Essler, S. Hauser, A. Yordanova, 2017, The Journal of Nuclear Medicine.

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

M. Essler, H. Ahmadzadehfar, C. Schlenkhoff, 2017, Clinical nuclear medicine.

Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.

M. Essler, H. Ahmadzadehfar, C. Schlenkhoff, 2016, Clinical nuclear medicine.